| Mary E Blackman, MD | |
|
79 Sand Pit Road, 102, Danbury, CT 06810-4010 | |
| (203) 749-5700 | |
| Not Available |
| Full Name | Mary E Blackman |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 38 Years |
| Location | 79 Sand Pit Road, Danbury, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013952910 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 029343 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Danbury Hospital | Danbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nuvance Health Medical Practice Ct Inc | 4789597691 | 648 |
News Archive
In Nature, VIB-K.U.Leuven researchers describe a new mechanism to enhance the restoration of the blood flow in ischemic diseases, which are among the leading causes of death worldwide.
The subject of the EU's BRIDGE project is transnational and interagency cooperation in the event of terror attacks, natural disasters and industrial accidents. The project is being led by SINTEF and was launched in April 2011.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the financing, Mr. Yoshitaka Kitao, CEO of SBI Holdings, Inc. and Mr. Robert Takeuchi, Director of SBI Investment Co., Ltd. will become members of the Quark board of directors.
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.
The benefits of computed tomography (CT) have increased greatly over the past decade. Now twice as powerful, it offers dynamic images of anatomy, including the beating heart. Future advancements promise to deliver even more clinical benefits. However, CT has always had a downside: it can deliver high radiation doses to patients, putting them at increased risk of developing cancer.
› Verified 2 days ago
| Entity Name | Nuvance Health Medical Practice Ct Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407898117 PECOS PAC ID: 4789597691 Enrollment ID: O20031205000130 |
News Archive
In Nature, VIB-K.U.Leuven researchers describe a new mechanism to enhance the restoration of the blood flow in ischemic diseases, which are among the leading causes of death worldwide.
The subject of the EU's BRIDGE project is transnational and interagency cooperation in the event of terror attacks, natural disasters and industrial accidents. The project is being led by SINTEF and was launched in April 2011.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the financing, Mr. Yoshitaka Kitao, CEO of SBI Holdings, Inc. and Mr. Robert Takeuchi, Director of SBI Investment Co., Ltd. will become members of the Quark board of directors.
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.
The benefits of computed tomography (CT) have increased greatly over the past decade. Now twice as powerful, it offers dynamic images of anatomy, including the beating heart. Future advancements promise to deliver even more clinical benefits. However, CT has always had a downside: it can deliver high radiation doses to patients, putting them at increased risk of developing cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mary E Blackman, MD 79 Sand Pit Road, Suite 102, Danbury, CT 06810-4010 Ph: (203) 749-5700 | Mary E Blackman, MD 79 Sand Pit Road, 102, Danbury, CT 06810-4010 Ph: (203) 749-5700 |
News Archive
In Nature, VIB-K.U.Leuven researchers describe a new mechanism to enhance the restoration of the blood flow in ischemic diseases, which are among the leading causes of death worldwide.
The subject of the EU's BRIDGE project is transnational and interagency cooperation in the event of terror attacks, natural disasters and industrial accidents. The project is being led by SINTEF and was launched in April 2011.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the financing, Mr. Yoshitaka Kitao, CEO of SBI Holdings, Inc. and Mr. Robert Takeuchi, Director of SBI Investment Co., Ltd. will become members of the Quark board of directors.
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.
The benefits of computed tomography (CT) have increased greatly over the past decade. Now twice as powerful, it offers dynamic images of anatomy, including the beating heart. Future advancements promise to deliver even more clinical benefits. However, CT has always had a downside: it can deliver high radiation doses to patients, putting them at increased risk of developing cancer.
› Verified 2 days ago
Dr. Shivayogi V Magavi, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 57 North St, Suite 103, Danbury, CT 06810 Phone: 203-744-7007 | |
Andrew Keller, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 27 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7155 | |
Nirmalamma S Magavi, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 57 North St, Suite 103, Danbury, CT 06810 Phone: 203-744-7007 | |
David D Weinshel, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7173 | |
Dr. Michael Spiegel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 33 Germantown Rd, 1st Floor, Danbury, CT 06810 Phone: 203-794-5600 Fax: 203-794-5611 | |
Michael Cohenuram, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7742 Fax: 203-830-2090 |